NCT00005792 - Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

June 2, 1998

Primary Completion Date

July 1, 2006

Study Completion Date

November 1, 2018

Conditions

Multiple MyelomaPlasma Cell Neoplasm

Interventions

DRUG

etoposide phosphate

Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3

DRUG

melphalan

Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5

DRUG

topotecan

Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5

PROCEDURE

Autologous Stem Cell Rescue

reinfusion of stem cells, Day 0

Trial Locations (1)

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa